IN2014MN01442A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01442A
IN2014MN01442A IN1442MUN2014A IN2014MN01442A IN 2014MN01442 A IN2014MN01442 A IN 2014MN01442A IN 1442MUN2014 A IN1442MUN2014 A IN 1442MUN2014A IN 2014MN01442 A IN2014MN01442 A IN 2014MN01442A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
acceptable salt
diabetes
type
compound
Prior art date
Application number
Other languages
English (en)
Inventor
Shigeo Yamanoi
Hidenori Namiki
Yuichi Ochiai
Madoka Hoshino
Koji Matsumoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of IN2014MN01442A publication Critical patent/IN2014MN01442A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IN1442MUN2014 2012-01-18 2013-01-17 IN2014MN01442A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012007840 2012-01-18
PCT/JP2013/050710 WO2013108800A1 (ja) 2012-01-18 2013-01-17 置換フェニルアゾール誘導体

Publications (1)

Publication Number Publication Date
IN2014MN01442A true IN2014MN01442A (es) 2015-07-03

Family

ID=48799224

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1442MUN2014 IN2014MN01442A (es) 2012-01-18 2013-01-17

Country Status (21)

Country Link
US (3) US9233958B2 (es)
EP (2) EP2805941B1 (es)
JP (2) JP6104181B2 (es)
KR (1) KR20140113688A (es)
CN (1) CN104159892A (es)
AU (1) AU2013210394A1 (es)
BR (1) BR112014017656A2 (es)
CA (1) CA2861847A1 (es)
CO (1) CO7020920A2 (es)
ES (2) ES2640667T3 (es)
HK (2) HK1220448A1 (es)
IL (1) IL233682A0 (es)
IN (1) IN2014MN01442A (es)
MX (1) MX2014008790A (es)
NZ (1) NZ627303A (es)
PH (1) PH12014501646A1 (es)
RU (1) RU2014133738A (es)
SG (1) SG11201404026SA (es)
TW (1) TWI551590B (es)
WO (1) WO2013108800A1 (es)
ZA (1) ZA201405108B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014008790A (es) 2012-01-18 2014-10-13 Daiichi Sankyo Co Ltd Derivado de fenilazol sustituido.
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
WO2017104782A1 (ja) * 2015-12-17 2017-06-22 第一三共株式会社 オキサジアゾール化合物の製造方法
EP3766879A1 (en) * 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
CN111388471B (zh) * 2020-03-03 2021-01-12 牡丹江医学院 一种治疗胆囊炎的药物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
EP1711491A1 (en) 2003-12-24 2006-10-18 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
EP1931660B1 (en) * 2005-09-29 2012-08-01 Sanofi Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
BRPI0710839A2 (pt) * 2006-04-06 2011-08-23 Prosidion Ltd agonistas heterocìclicos de gpcr
GB0606913D0 (en) * 2006-04-06 2006-05-17 Prosidion Ltd Compounds
KR20100033419A (ko) * 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 rup3 또는 gpr119 수용체의 작용제로서 n-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
KR101536021B1 (ko) 2007-10-16 2015-07-10 다이이찌 산쿄 가부시키가이샤 피리미딜 인돌린 화합물
EP2241558A1 (en) 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
TW201039827A (en) 2009-04-15 2010-11-16 Daiichi Sankyo Co Ltd Indoline compound
AU2010279964B2 (en) 2009-08-05 2016-02-11 Daiichi Sankyo Company, Limited Amide derivative
JP5546543B2 (ja) 2009-08-05 2014-07-09 第一三共株式会社 スルホン誘導体
SI2628733T1 (sl) * 2010-10-14 2015-10-30 Daiichi Sankyo Company, Limited Derivati acilbenzena
JP5973440B2 (ja) 2011-07-29 2016-08-23 第一三共株式会社 N−ヘテロ環置換アミド誘導体
MX2014008790A (es) 2012-01-18 2014-10-13 Daiichi Sankyo Co Ltd Derivado de fenilazol sustituido.

Also Published As

Publication number Publication date
AU2013210394A1 (en) 2014-08-14
ES2602962T3 (es) 2017-02-23
US20140357675A1 (en) 2014-12-04
TWI551590B (zh) 2016-10-01
EP2805941A1 (en) 2014-11-26
AU2013210394A2 (en) 2014-10-16
CA2861847A1 (en) 2013-07-25
EP3009433B1 (en) 2017-06-21
PH12014501646A1 (en) 2014-10-13
JP2017052800A (ja) 2017-03-16
HK1200824A1 (en) 2015-08-14
EP2805941B1 (en) 2016-08-17
EP2805941A4 (en) 2015-08-05
MX2014008790A (es) 2014-10-13
SG11201404026SA (en) 2014-11-27
CO7020920A2 (es) 2014-08-11
RU2014133738A (ru) 2016-03-10
EP3009433A1 (en) 2016-04-20
US9233958B2 (en) 2016-01-12
TW201335141A (zh) 2013-09-01
KR20140113688A (ko) 2014-09-24
JPWO2013108800A1 (ja) 2015-05-11
WO2013108800A1 (ja) 2013-07-25
CN104159892A (zh) 2014-11-19
ES2640667T3 (es) 2017-11-03
ZA201405108B (en) 2015-10-28
IL233682A0 (en) 2014-09-30
JP6104181B2 (ja) 2017-03-29
US20160081993A1 (en) 2016-03-24
HK1220448A1 (zh) 2017-05-05
US20160090375A1 (en) 2016-03-31
BR112014017656A2 (pt) 2017-06-27
US9725438B2 (en) 2017-08-08
NZ627303A (en) 2015-11-27

Similar Documents

Publication Publication Date Title
NZ601121A (en) 5-alkynyl-pyrimidines
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
MY169745A (en) Purinone derivative
MX348564B (es) Tetrahidrocannabivarina para usarse en la protección de células de los islotes pancreáticos.
WO2013019561A8 (en) Nuclear transport modulators and uses thereof
WO2012117000A8 (en) 3-amino-pyridines as gpbar1 agonists
IN2014MN01442A (es)
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
PH12014502805A1 (en) Novel indanesulfamide derivative
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
PH12014502802A1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
IN2014DN05972A (es)
WO2013155528A3 (en) Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels
CY1116303T1 (el) Παραγωγο ακυλβενζολιου
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
WO2011159124A3 (ko) Interleukin-6 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MX2012001107A (es) Derivado de amida.
MX2014000929A (es) Derivados de amida sustituidos con n-hetero-anillo.
MX2012006287A (es) Activadores de azaindol glucocinasa.
CA2836488C (en) Methods for treating obesity and/or metabolic syndrome
MX2012012410A (es) Agente terapeutico y agente preventivo para enfermedad de alzheimer.
WO2012091425A3 (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물
CA2863110A1 (en) 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators
WO2011026193A8 (en) Cytotoxic compounds
UA52171U (ru) Способ лечения дезадаптации сердечно-сосудистой системы у новорожденных с синдромом аспирации мекония